Prior Therapy With Pegylated-Interferon Alfa-2b Improves the Efficacy of Adjuvant Pembrolizumab in Resectable Advanced Melanoma.

Front Oncol · 2021 · PMC8243982 · PMID 34221994

Europe PMC DOI

hedged sentences

0.2914

closest p · 5.8× alpha

0.2914

boldest claim

The sentences

did not reach statistical significanceP = 0.2914not close (p > 0.1)

However, this trend did not reach statistical significance (median RFS Pem 7.1 months vs . 3.6 months, HR=0.51, 95% CI 0.17-1.51; P = 0.2914) ( Figure 5C ).

also in 111,027 other papers

showed a trendno p-value reported

Subgroup analysis on the impact of prior PEG-IFN-α treatment on RFS Pem showed a trend towards better clinical response to adjuvant pembrolizumab for patients with acral melanoma who received prior PEG-IFN-α therapy (median RFS Pem 8.5 months vs . 5.4 months, Figure S3A ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.